Workshop on Defining the FTD & ALS Spectrum
September 18, 2024 9AM-1PM
(preceding ISFTD September 19-21, 2024)
Corey McMillan, Michael Benatar, & John van Swieten
There is increasing conceptual recognition that frontotemporal degeneration (FTD) and amyotrophic lateral sclerosis (ALS) represent the extreme ends of a complex clinical, pathological, and genetic spectrum. However, despite the concept of an ALS-FTD spectrum, in practice there remains minimal interaction and consensus between the FTD and ALS research communities. This lack of interaction risks duplicity or inconsistencies in our definitions of the biology and clinical concepts of ALS and/or FTD. Moreover, TDP-43 which commonly brings together ALS and FTD is also associated with aging and non-CNS disorders which challenge concepts from within our communities. We therefore propose a half-day workshop to precede the ISFTD 2024 meeting to learn from multiple perspectives both within the FTD and ALS communities and beyond. The tentative program includes:
Strategies to Establish a Framework and Improve Nomenclature to Bridge Gaps in FTD & ALS Spectrum.
-
Michael Benatar and Corey McMillan
Clinical Perspectives
Multi-disease Perspectives from Adjacent Disorders
-
Clinical & Pathological Perspectives of LATE TDP-43: pending speaker
-
Cognition & Behavior in PMA & PLS: Michael van Es
-
Molecular & Clinical Lessons from VCP
-
Molecular: Eddie Lee
-
Clinical: Lindsay Alfano
-
Lessons from Less Frequent Phenotypic Variants
-
Motor & Cognitive Features of Language Disorders in ALS: Niall Pender
-
Cognition & Behavior in SOD1 ALS: Monica Consonni
-
Neuropsychiatric & Psychosis Features of ALS and FTD: Ted Huey
Biomarkers of Biology Across Phenotypic Spectrums of ALS & FTD
-
Biofluid biomarkers of tau and TDP: specificity and lack thereof: Kathryn Cousins
-
Emerging TDP-43 biomarkers: Len Petrucelli